4/A: Alkermes Director Corrects Equity Vesting Terms
Amendment to Statement of Changes in Beneficial Ownership
Director Richard Gaynor filed an amendment to a Form 4 to correct the vesting schedule for previously granted stock options and restricted stock units.
Summary
- Director Richard Gaynor received a grant of 11,538 non-qualified stock options and 5,409 restricted stock units (RSUs) on May 20, 2026.
- This filing serves as an amendment to the original Form 4 filed on May 22, 2026, to rectify an error in the reported vesting terms.
- The corrected vesting schedule stipulates that awards vest in full on the earlier of the one-year anniversary of the grant date or the date of the next annual general meeting occurring at least 50 weeks after the grant date.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative event, as it represents a correction of a clerical error rather than a change in company strategy or financial performance.
Positives
- Transparency in correcting administrative reporting errors regarding director compensation.
Negatives
- Initial administrative error in reporting the vesting terms of director equity awards.
Risks
- None identified; this is a routine administrative correction.
Future Outlook
The filing does not provide forward-looking business guidance, focusing solely on the correction of director equity vesting terms.
Industry Context
StockSavvy.ai notes that administrative amendments to Form 4 filings are common in the biopharmaceutical sector, where complex equity compensation structures are standard for attracting and retaining board talent.
Comparison to Industry Standards
- The vesting schedule (one-year cliff or next AGM) is consistent with standard corporate governance practices for non-employee director compensation in the U.S. biotech industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Correction of Disclosure | Correction of vesting terms for director equity awards. | 05/22/2026 | Minimal; ensures accurate public record of director compensation. |
Stakeholder Impact
- Shareholders are provided with accurate information regarding director equity incentives.
Next Steps
- Vesting of the equity awards on the earlier of the one-year anniversary of the grant or the next annual general meeting.
Key Dates
| Date | Description |
|---|---|
| 05/20/2026 | Date of the original equity grant and earliest transaction. |
| 05/20/2036 | Expiration date for the non-qualified stock options. |
| 05/22/2026 | Date of the original Form 4 filing and the amendment filing. |
Keywords
Alkermes, ALKS, Director Compensation, Equity Vesting, SEC Form 4/A, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.